Total
0
Shares
ice - The Market Herald
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) expects more data to be released in the coming months from several clinical studies of its anti-infectives
  • The company says first patient dosing will get underway in August for its Intravenous (I.V.) Phase I Human Clinical Trial, which is set to run for one year
  • By Q4 2021, RCE expects data to begin arriving from its Topical Phase I/II Human Burns Study, with the eight-month trial recently getting underway in WA
  • Around the same time, Recce says it should also begin receiving data from its SARS-CoV-2 (COVID-19) International Studies despite a recent delay
  • Company shares are down 1.38 per cent at $1.07 per share

Recce Pharmaceuticals (RCE) is expecting more data to be released in the coming months from several clinical studies of its anti-infectives.

The company has released a wide-ranging update on four of its studies, which are being carried out in Australia and abroad.

Firstly, RCE said patient dosing will get soon underway for its year-long Intravenous (I.V.) Phase I Human Clinical Trial. Recce is testing its synthetic antibiotic RECCE 327 (R327) as part of this trial, with first dosings to begin in August.

Then in Q4 2021, RCE will see data begin arriving from its Topical Phase I/II Human Burns Study. This eight-month-long trial also involves R327 and recently got underway at the Fiona Stanley Hospital in WA.

Around the same period of time, Recce said it may begin receiving data from its SARS-CoV-2 (COVID-19) International Studies.

However, the company noted its COVID-19 animal studies of R327 and as well as its RECCE 529 synthetic anti-viral compound (R529) are taking longer than anticipated due to poor infection levels amongst the animals.

The company has brought on board an additional facility to help fix the issue, with hopes testing of Alpha and Beta COVID-19 strains will arrive from Q4.

Finally, RCE said it had advanced to the next stage of testing its synthetic antibiotic RECCE 435 (R435) oral compound against Helicobacter pylori (H. pylori).

It's expecting results from this latest stage of testing to begin arriving from next month.

Shares in Recce Pharmaceuticals were down 1.38 per cent at $1.07 per share at 3:26 pm AEST.

RCE by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.